No abstract

No abstract

No abstract

Fabricating perovskite solar cells (PSCs) in ambient air condition is beneficial for lowering the processing cost and boosting the commercialization. Formamidinium lead iodide (FAPbI 3 ) is an attractive candidate for efficient PSCs; however, it easily suffers from degradation and phase transition in the presence of ambient moisture. Methylammonium (MA) cation is commonly incorporated to stabilize FAPbI 3 , whereas the residual MA tends to deteriorate the thermal and operational stability. Herein, we report a MA-free strategy to fabricate high-quality α-FAPbI 3 films and inverted PSCs under open air conditions with a relative humidity (RH) of 60 ± 10%. The incorporation of phenylethylammonium iodide (PEAI) effectively inhibits the decomposition and phase transition of FAPbI 3 during its crystallization in humid air. Accordingly, phase-pure α-FAPbI 3 perovskite films with significantly reduced δ-FAPbI 3 and PbI 2 content are successfully obtained. In addition, introducing PEAI strongly enhances the crystallinity of FAPbI 3 perovskite films, thereby yielding enlarged grain sizes and reduced grain boundaries. Defects at the grain boundaries and surface are further passivated by PEAI addition, so that the trap state density is significantly decreased. As a result, the non-radiative recombination is effectively suppressed and the charge carrier transport is promoted. The inverted device optimized with a suitable PEAI concentration exhibits an enhanced power conversion efficiency (PCE) of 17.83%, which significantly surpasses the control device (12.29% PCE). Moreover, the PEAI optimized FAPbI 3 PSCs demonstrate strongly improved long-term stability, with nearly 97% PCE maintained after 27-day storage under ambient conditions. This work provides a feasible way to fabricate PSCs in ambient air for promoting their wide range of applications.

The pathophysiology of autistic spectrum disorder (ASD) is not fully understood and there are no diagnostic or predictive biomarkers. Extracellular vesicles (EVs) are cell-derived nano-sized vesicles, carrying nucleic acids, proteins, lipids and other bioactive substances. As reported, serum neural cell adhesion molecule L1 (L1CAM)-captured EVs (LCEVs) can provide reliable biomarkers for neurological diseases; however, little is known about the LCEVs in children with ASD. In this study, serum samples were collected from 100 ASD children and 60 age-matched typically developed (TD) children. LCEVs were isolated and characterized meticulously. Whole-transcriptome of LCEVs was analyzed by lncRNA microarray and RNA-Sequencing. All raw data was submitted on GEO Pro les, and GEO accession numbers is GSE186493. RNAs expressed differently in LCEVs from ASD sera vs. TD sera were screened, analyzed, and further validated. A total of 1418 mRNAs, 1745 lncRNAs and 11 miRNAs were differentially expressed, and most of them were down-regulated in ASD. Most RNAs were involved in neuron-and glycan-related networks implicated in ASD. The levels of EDNRA, SLC17A6, HTR3A, OSTC, TMEM165, PC-5p-139289_26, and hsa-miR-193a-5p changed signi cantly in ASD. In conclusion, whole-transcriptome analysis of serum LCEVs reveals neural and glycosylation changes in ASD, which may help detect predictive biomarkers and molecular mechanisms of ASD, and provide reference for diagnoses and therapeutic management of the disease.